壹评级:康方生物依沃西数据更新,创新药双抗赛道确定性提升

第一财经
Jul 24

康方生物海外合作伙伴Summit更新了依沃西全球Ⅲ期HARMONi研究的生存数据,西方患者总生存风险比改善至0.76。第一财经“壹评级”认为,该数据实质性回应了市场对中国创新药海外适用性的核心质疑,跨人种疗效一致性得到验证,该药物的全球注册价值进一步凸显。   “壹评级”指出,随访延长带来的风险比持续优化,体现了免疫治疗的拖尾效应。欧美患者获益趋势与中国数据趋于一致,有效消除了因人种差异而引发的...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10